Figure 1.
Combined regimen stands for inopressors and inodilators; *patients excluded for missing data concerning the treatment regimen, the outcome or the length of hospital stay; $patients included in the final analysis.
Table 1.
Patients’ characteristics and differences between the two treatment groups.
Figure 2.
Standard differences in the major baseline covariates between the two treatment regimens.
NYHA, New York Heart Association; PCI, percutaneous intervention; IABP, intra-aortic balloon pump; CPAP, continuous positive airway pressure; HR, heart rate; BNP, B-type natriuretic peptide; ACS, acute coronary syndrome; CAD, coronary artery disease; CHF, chronic heart failure; ACEI/ARB, angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers; BB, beta blockers; SBP, systolic blood pressure; LVEF, left ventricular ejection fraction.
Table 2.
Patients’ characteristics and differences between the two treatment groups after PS weighting.
Figure 3.
Kaplan-Meier representation of mortality: A.
As evaluated in the original pooled datasets; B. as evaluated in the pooled datasets after PS weighting. (Combined regimen stands for inopressors and inodilators).
Figure 4.
Subgroup PS-weighted analyses of the inopressors and inodilators vs. inopressors alone on short-term mortality.
HR, hazard ratios; PS, propensity score; SBP, systolic blood pressure; ACS, acute coronary syndrome.